Zegalogue vs Glucagon: Product Comparison for Emergency Hypoglycemia Treatment
Abstract: Zegalogue (dasiglucagon) and traditional glucagon offer distinct profiles for severe hypoglycemia. Zegalogue, a stable liquid peptide analog, provides faster reconstitution and injection, improving usability versus powdered glucagon’s complex mixing. Market trends favor ready-to-use devices, driving Zegalogue’s adoption despite higher cost. Both products share identical efficacy in raising blood glucose, but Zegalogue’s enhanced stability and lower error risk represent key technical advantages. Regulatory approvals (FDA, EMA) confirm safety. For selection, prioritize device simplicity, storage logistics (room temperature stability), and patient training needs. The peptide hypoglycemia market is expanding, with Zegalogue leading innovation in emergency glucagon delivery.